Business Description
Zhejiang Hisun Pharmaceutical Co Ltd
NAICS : 325412
ISIN : CNE0000013Z2
Share Class Description:
SHSE:600267: Class ACompare
Compare
Traded in other countries / regions
600267.China IPO Date
2000-07-25Description
Zhejiang Hisun Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is focused on the research, development, and distribution of pharmaceuticals. It produces and supplies antibiotics and anticancer drugs. The company's research channels cover indications like anticancer, cardiovascular, anti-infective, anti-parasitic, immunosuppressant and others. Its product portfolio includes active pharmaceutical ingredients like Anastrozole, Docetaxel, Methotrexate, and others and finished dosages such as letrozole tablets, anastrozole tablets, injection mitomycin, and others.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.32 | |||||
| Equity-to-Asset | 0.51 | |||||
| Debt-to-Equity | 0.57 | |||||
| Debt-to-EBITDA | 35.68 | |||||
| Interest Coverage | 2.78 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 1.58 | |||||
| Beneish M-Score | -3.08 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -8.7 | |||||
| 3-Year EBITDA Growth Rate | -23.5 | |||||
| 3-Year FCF Growth Rate | 5.4 | |||||
| 3-Year Book Growth Rate | -1 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 49.79 | |||||
| 9-Day RSI | 49.24 | |||||
| 14-Day RSI | 51.6 | |||||
| 6-1 Month Momentum % | 8.4 | |||||
| 12-1 Month Momentum % | -17.58 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.93 | |||||
| Quick Ratio | 0.65 | |||||
| Cash Ratio | 0.24 | |||||
| Days Inventory | 116.86 | |||||
| Days Sales Outstanding | 79.38 | |||||
| Days Payable | 77.75 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Dividend Growth Rate | 50.4 | |||||
| 3-Year Average Share Buyback Ratio | -7.8 | |||||
| Shareholder Yield % | 10.03 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 40.15 | |||||
| Operating Margin % | 5.01 | |||||
| Net Margin % | -0.21 | |||||
| FCF Margin % | 16.02 | |||||
| ROE % | -0.25 | |||||
| ROA % | -0.12 | |||||
| ROIC % | 3.58 | |||||
| ROC (Joel Greenblatt) % | 1.44 | |||||
| ROCE % | 1.25 | |||||
| Years of Profitability over Past 10-Year | 7 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 22.85 | |||||
| PE Ratio without NRI | 30.99 | |||||
| Shiller PE Ratio | 70.5 | |||||
| PS Ratio | 1.07 | |||||
| PB Ratio | 1.24 | |||||
| Price-to-Tangible-Book | 1.41 | |||||
| Price-to-Free-Cash-Flow | 6.51 | |||||
| Price-to-Operating-Cash-Flow | 6.03 | |||||
| EV-to-EBIT | 101.91 | |||||
| EV-to-EBITDA | 101.91 | |||||
| EV-to-Revenue | 1.4 | |||||
| EV-to-FCF | 8.77 | |||||
| Price-to-Projected-FCF | 0.64 | |||||
| Price-to-Median-PS-Value | 0.88 | |||||
| Price-to-Graham-Number | 1.39 | |||||
| Earnings Yield (Greenblatt) % | 0.98 | |||||
| FCF Yield % | 14.96 | |||||
| Forward Rate of Return (Yacktman) % | 0.85 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Zhejiang Hisun Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 9,546.718 | ||
| EPS (TTM) (Â¥) | -0.02 | ||
| Beta | 1.03 | ||
| Volatility % | 29.91 | ||
| 14-Day RSI | 51.6 | ||
| 14-Day ATR (Â¥) | 0.20932 | ||
| 20-Day SMA (Â¥) | 8.5375 | ||
| 12-1 Month Momentum % | -17.58 | ||
| 52-Week Range (Â¥) | 6.43 - 10.32 | ||
| Shares Outstanding (Mil) | 1,207.87 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Zhejiang Hisun Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Zhejiang Hisun Pharmaceutical Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Zhejiang Hisun Pharmaceutical Co Ltd Frequently Asked Questions
What is Zhejiang Hisun Pharmaceutical Co Ltd(SHSE:600267)'s stock price today?
The current price of SHSE:600267 is ¥8.46. The 52 week high of SHSE:600267 is ¥10.32 and 52 week low is ¥6.43.
When is next earnings date of Zhejiang Hisun Pharmaceutical Co Ltd(SHSE:600267)?
The next earnings date of Zhejiang Hisun Pharmaceutical Co Ltd(SHSE:600267) is .
Does Zhejiang Hisun Pharmaceutical Co Ltd(SHSE:600267) pay dividends? If so, how much?
Zhejiang Hisun Pharmaceutical Co Ltd(SHSE:600267) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers